Vfend

Vfend (generic name: voriconazole) is an antifungal drug from the triazole family that prevents fungal growth of opportunistic human Candida-based yeast pathogens that cause infections when the host is immunocompromised or debilitated. Triazole acts to disrupt the formation of ergosterol, an essential component of fungal cell membranes. Without a functional cell membrane, the fungus is prevented from spreading. Candida fungal infections are often life-threatening. Vfend is used for the treatment of adults and children over the age of two who have one of the following fungal infections: invasive aspergillosis candidemia in patients with a normal white blood cell count infections caused by candida that is resistant to fluconazole (an alternate antifungal medicine) infections caused by scedosporium or fusarium fungus Vfend is intended mainly for patients with worsening and possibly life-threatening infections or to prevent invasive fungal infections in patients who have undergone a hematopoietic stem-cell transplant and are at high risk of infection.